Vivoryon Therapeutics
Biopharmaceutical company focused on the development of innovative small molecule drugs.
Launch date
Employees
Market cap
AUD92.2m
Enterprise valuation
AUD44m (Public information from Sep 2024)
Share price
€2.105 VVY.AS
Halle (Saale) Saxony-Anhalt (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 10.8m | - | (3.6m) | 5.0m | - | - |
| % growth | - | - | - | - | (238 %) | - | - |
| EBITDA | (16.3m) | (12.0m) | (28.2m) | (28.4m) | (22.5m) | (15.8m) | (17.0m) |
| % EBITDA margin | - | (111 %) | - | 783 % | (450 %) | - | - |
| Profit | (16.5m) | (12.7m) | (28.2m) | (28.3m) | (26.1m) | (17.1m) | (19.7m) |
| % profit margin | - | (118 %) | - | 783 % | (523 %) | - | - |
| EV / revenue | - | 34.0x | - | -53.5x | 8.7x | - | - |
| EV / EBITDA | -9.4x | -30.6x | -7.8x | -6.8x | -1.9x | -3.6x | -4.6x |
| R&D budget | 13.2m | 17.5m | 20.2m | 17.6m | - | - | - |
| R&D % of revenue | - | 162 % | - | (487 %) | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
$20.6m | Series A | ||
| N/A | $20.6m | Series A | |
$54.0m | Series B | ||
€15.0m | Late VC | ||
| N/A | €23.2m Valuation: €102m | IPO | |
* | N/A | €21.0m | Private Placement VC |
* | N/A | €25.0m | Private Placement VC |
| Total Funding | AUD251m | ||